Better healthcare with automated treatments

aEyeTX is an Automated Treatment Regime combining healthcare systems with AI to diagnose and manage the treatment of eye disease.

People shouldn’t go blind, while waiting in line

Age-related macular degeneration (AMD) is the most common cause of blindness in developed countries. Worldwide, 196 million people live with AMD, and the number is expected to increase by 70% before 2040 as the population ages. In addition, approximately 10% of patients suffer from the highly treatable neovascular or "wet" AMD. Yet, the cost of manual processes and lack of trained ophthalmologists mean that too many patients go blind while waiting for access to treatment.

aEyeTX wants to revolutionise, transform and automate healthcare to preserve the vision of the millions of people still waiting in line to see a doctor.

Book meeting
cristian-newman-l9I93gZKTG4-unsplash 2
alpay-tonga-Sp82b8oJYyc-unsplash 2
rafael-leao-NRnPv3Gs-Nc-unsplash 2
angelina-litvin-52R7t7x8CPI-unsplash 2
doctor-and-nurse-examine-x-rays 1

Free up scarce resources and improve quality of treatment within existing systems

Age-related macular degeneration (AMD) is a chronic retinal disease that affects central vision. It is the most common cause of blindness in the Western World. AMD patients routinely live with lifelong, stressful procedures as the patients must be examined frequently, and the transport time to and from eye clinics can be long and exhausting. Furthermore, eye clinics are challenged by the costs of manual processes, updates to healthcare systems, maintaining high standards, and a shortage of trained ophthalmologists. Simultaneously, the number of AMD patients is further proliferating.

By using an AI as a decision support tool in the clinical workflows, non-medical staff can manage controls and free up very scarce ophthalmologist resources. aEyeTX can autonomously assess which patients should be treated, which patients should be observed in the clinic, and identify patients where further treatment is futile.

aEyeTX can work with any OCT scanner to assess the progression of wet AMD. aEyeTX adeptly integrates with the ever-changing best practices of any healthcare setting.

From the Healthcare Science Lab of Enversion

aEyeTX is developed by a team of data scientists and engineers at Enversion Healthcare Science Lab and based on scientific research collaboration with leading ophthalmologists at the most prominent eye clinic in Scandinavia.

Enversion team

How it works


Upcoming milestones

While aEyeTX already offers great utility we see an even bigger potential that will be explored in the future. Due to this, our current readmap looks like this:

  • Enrollment of +230 patients for clinical trials

  • Publication of a further article evaluating the whole system

  • Publication of an article that demonstrates the efficacy of earlier detection of nAMD to identify and treat even more patients before their vision becomes severely impaired. (A retrospective study has already been conducted)

Expanding with an algorithm that enables screening for abnormalities in the demographic

Expanding with additional treatment regimens for other common eye diseases such as diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma ect.

Expanding with treatment regimens of neurodegenerative disorders such as Parkinson's and Alzheimer's disease. Connecting OCT scans with the cross-track cohort

Expanding with treatment regimens of cardiovascular disease such as coronary heart disease, strokes and TIAs. Connecting OCT scans with the cross-track cohort

Get in touch today

We'll be happy to get back to you with more information about aEyeTX's capabilities and prospects. Give us a few details, and you will get a call or mail from us as soon as possible.